SARS-CoV-2-Infection in People Addicted to Illegal Drugs – Is There a Protective Effect of Opioid Maintenance Treatment?

Abstract

Introduction People addicted to illegal drugs were discussed as a risk group for SARS-CoV-2 infections, with increased susceptibility and a severe course of infection.

Methods In this study, the frequency of SARS-CoV-2 infections of drug-dependent persons admitted to inpatient detoxification treatment in five psychiatric hospitals was determined by implementing routine polymerase chain reaction (PCR)-testing at admission (9/2020) up to one year. Main substance-related diagnosis, comorbid respiratory disease, housing situation, and current opioid maintenance treatment (OMT) were documented. An age-matched control group of psychiatric inpatients without dependence from illegal drugs was established.

Results Data from 1675 patients (male 79.5%; mean age 39.5 years; opioid dependence 81.5% homelessness; 2.4%; chronic respiratory disease 6.3%) were included. Out of 1365 patients dependent on opioids, 50.2% were currently in OMT. Six (3 female; mean age 40.3 years) patients tested positive for SARS-CoV-2 by PCR (0.36%), and none showed symptoms of COVID-19. All six were opioid dependent, 5 currently not in OMT. In the control group, 11 out of 1811 inpatients tested positive (0.61%).

Discussion The rate of SARS-CoV-2-infections in persons with dependence on illegal drugs was not increased compared to a control group of psychiatric patients. OMT is presumably a protective factor, e. g. in the participating cities, OMT facilities offered an easy access to vaccination programs. In contrast, drug addicts in the USA were severely affected by the pandemic. Differences between countries might partially be explained by social factors such as the higher availability of OMT in Germany and a much lower frequency of homelessness.

Keywords

opioid addiction - SARS-CoV-2 - risk factors - prevention - opioid maintenance treatment

Publikationsverlauf

Eingereicht: 01. Februar 2024
Eingereicht: 26. April 2024

Angenommen: 05. Juni 2024

Artikel online veröffentlicht:
01. August 2024

• References

• 1 Lai C, Shih T, Ko W. et al. Severe respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 55: 105924
• 2 Patel I, Walter LA, Li L. Opioid overdose crises during the COVID-19 pandemic: Implication of health disparities. Harm Reduct J 2021; 18: 89
• 3 Khan KS, Mamun MA, Griffiths MD. et al. The mental health impact of the COVID-19 pandemic across different Cohorts. Int J Ment Health Addict 2022; 20: 380-386
• 4 Patel JA, Nielsen FH, Badiani A. et al. Poverty, inequality and COVID-19: The forgotten vulnerable. Public Health 2020; 183: 110-111
• 5 Farhoudian A, Baldacchino A, Clark N. et al. COVID-19 and substance use disorders: Recommendations to a comprehensive healthcare response. An International Society of Addiction Medicine Practice and Policy Interest Group Position Paper. Basic Clin Neurosci 2020; 11: 133-150
• 6 Schimmel J, Manini AF. Opioid use disorder and COVID-19: Biological plausibility für worsened outcomes. Subst Use Misuse 2020; 55: 1900-1901
• 7 Baillargeon J, Polychronopoulou E, Kuo YF. et al. The impact of substance use disorder on COVID-19 outcomes. Psychiatr Serv 2021; 72: 578-581
• 8 EMCDDA. Impact of COVID-19 on drug markets, use, harms and drug services in the community and prisons: Results from an EMCDDA trendspotter study. Luxembourg: Publications Office of the European Union; 2021
• 9 Oette M, Corpora S, Baron M. et al. The prevalence of SARS-CoV-2 infection among homeless persons in Cologne, Germany—an epidemiological study at the height of the third wave. Dtsch Arztebl Int 2021; 118: 678-679
• 10 Wang Q, Kaelber DC, Volkow ND. et al. COVID-19 risk and outcomes in patients with substance abuse disorders: Analyses from electronic health records in the United States. Mol Psychiatry 2021; 26: 30-39
• 11 Bruggmann P, Senn O, Frei A. et al. High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich. A cross-sectional study. Swiss Med Wkly 2022; 152: w30122
• 12 Fenton F, Stokes S, Eagleton M. A cross-section observational study on the seroprevalence of antibodies to COVID-19 in patients receiving opiate agonist treatment. Ir J Med Sci 2022; 191: 1053-1058
• 13 Vallecillo G, Perelló R, Güerri R. et al. Clinical impact of COVID-19 on people with substance use disorders. J Public Health (Oxf) 2021; 43: 9-12
• 14 Rassweiler-Seyfried MC, Miethke T, Becker KP. et al. Results of preoperative SARS-CoV-2 testing in the coronavirus pandemic. Urologe A 2021; 331-336
• 15 Kraus L, Seitz NN, Schulte B. et al. Estimation of the number of people with opioid addiction in Germany. Dtsch Arztebl Int 2019; 116: 137-143
• 16 Neuhauser H, Buttmann-Schweiger N, Ellert U. et al. Seroepidemiologische Studien zu SARS-CoV-2 in Stichproben der Allgemeinbevölkerung und bei Blutspenderinnen und Blutspendern in Deutschland – Ergebnisse bis August 2021. Epid Bull 2021; 37: 3-12
• 17 Schecke H, Specka M, Deimel D. et al. Substitutionsbehandlung Opioidabhängiger unter den Bedingungen der COVID-19 Pandemie – regionale Ergebnisse aus Nordrhein [Opioid maintenance therapy during COVID-19 – regional results from Germany]. Suchttherapie 2024; 25: 16-21
• 18 Specka M, Kröckert T, Trilling M. et al. Opiate maintenance patients´ attitudes and self-reported adherence to protective measures against SARS-CoV-2 infections. Front Psychiatry 2023; 14: 1254053
• 19 Soares WE, Melnick ER, Nath B. et al. Emergency department visits for nonfatal opioid overdose during the COVID-19 pandemic across six US health care systems. Ann Emerg Med 2022; 79: 158-167
• 20 Garcia GP, Stringfellow EJ, DiGennaro C. et al. Opioid overdose decedent characteristics during COVID-19. Ann Med 2022; 54: 1081-1088
• 21 Jahresbericht der Drogenbeauftragten 2020 [Annual report of the federal drug officer 2020]. Die Drogenbeauftragte der Bundesregierung beim Bundesministerium für Gesundheit. 2020 https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Drogen_und_Sucht/Berichte/Broschuere/DSB_Jahresbericht_2020_bf.pdf (accessed April 22, 2024)
• 22 Krawczyk N, Rivera BD, Jent V. et al. Has the treatment gap for opioid use disorder narrowed in the U.S.? A yearly assessment from 2010 to 2019. Int J Drug Policy 2022; 110: 103786
• 23 KVNO - (Kassenärztliche Vereinigung Nordrhein). Informationen zur Opioid-Substitution und Sars-CoV-2/Covid-19 [Information on opioid maintenance treatment and Sars-CoV-2/Covid-19]. 2020 https://www.kvno.de/fileadmin/shared/pdf/online/genehmigungen/substitution/substitution_corona.pdf (accessed April 22, 2024)
• 24 Krawczyk N, Fawole AYJ, Tofighi B. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic. A scoping review. Addict Sci Clin Pract 2021; 16: 68
• 25 Krawczyk N, Williams AR, Saloner B. et al. Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings. J Subst Abuse Treat 2021; 126: 108329
• 26 Hotton A, Mackesy-Amiti ME, Boodram B. Trends in homelessness and injection practices among young urban and suburban people who inject drugs: 1997-2017. Drug Alcohol Depend 2021; 225: 108797
• 27 Riss GL, Chang DI, Wevers C. et al. Opioid maintenance therapy restores CD4+ T cell function by normalizing CD4+CD25(high) regulatory T cell frequencies in heroin user. Brain Behav Immun 2012; 26: 972-978
• 28 Brown KG, Chen CY, Dong D. et al. Has the United States reached a plateau in overdoses caused by synthetic opioids after the onset of the COVID-19 pandemic? Examination of centers for disease control and prevention data to November 2021. Front Psychiatry 2022; 13: 947603
• 29 Lutfy K. Opioid crisis – An emphasis on fentanyl analogs. Brain Sci 2020; 10: 485
• 30 Wittchen HU, Apelt SM, Soyka M. et al. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: A naturalistic study in 2694 patients. Drug Alcohol Depend 2008; 95: 245-257
• 31 Eagleton M, Stokes S, Fenton F. et al. Does opioid substitution treatment have a protective effect on the clinical manifestations of COVID-19?. Comment on Br J Anaesth 2020; 125: e382-e383 Br J Anaesth 2021; 126: e114–e116